AxoGen, Inc. (AXGN)

NASDAQ: AXGN · IEX Real-Time Price · USD
9.38
-0.52 (-5.25%)
Feb 6, 2023, 3:08 PM EST - Market open
-5.25%
Market Cap 394.11M
Revenue (ttm) 133.96M
Net Income (ttm) -28.82M
Shares Out 42.29M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 234,563
Open 9.92
Previous Close 9.90
Day's Range 9.03 - 10.02
52-Week Range 6.87 - 13.66
Beta 0.52
Analysts Buy
Price Target 17.51 (+86.67%)
Earnings Date Mar 14, 2023

About AXGN

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Ms. Karen Zaderej
Employees 428
Stock Exchange NASDAQ
Ticker Symbol AXGN
Full Company Profile

Financial Performance

In 2021, Axogen's revenue was $127.36 million, an increase of 13.41% compared to the previous year's $112.30 million. Losses were -$26.99 million, 13.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AXGN stock is "Buy." The 12-month stock price forecast is $17.51, which is an increase of 86.67% from the latest price.

Price Target
$17.51
(86.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022

ALACHUA, Fla. and TAMPA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

1 month ago - GlobeNewsWire

Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference

ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

1 month ago - GlobeNewsWire

Axogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donation

ALACHUA, Fla. and TAMPA, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

1 month ago - GlobeNewsWire

Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)

If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price St...

3 months ago - Zacks Investment Research

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Axogen, Inc Reports 2022 Third Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

3 months ago - GlobeNewsWire

Axogen to Participate at Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

3 months ago - GlobeNewsWire

Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.

Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine. Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of ...

3 months ago - GlobeNewsWire

AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know

AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022

ALACHUA and TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...

3 months ago - GlobeNewsWire

AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...

4 months ago - Zacks Investment Research

Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand

Industry leading nerve repair surgeons will discuss data-driven best practices during symposium session Industry leading nerve repair surgeons will discuss data-driven best practices during symposium ...

4 months ago - GlobeNewsWire

Wall Street Analysts Think AxoGen (AXGN) Could Surge 89%: Read This Before Placing a Bet

The consensus price target hints at an 89.4% upside potential for AxoGen (AXGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

6 months ago - Zacks Investment Research

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Axogen, Inc Reports 2022 Second Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

6 months ago - GlobeNewsWire

Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference

ALACHUA. Fla. and TAMPA, Fla, July 29, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...

6 months ago - GlobeNewsWire

Axogen, Inc. Announces Organizational Updates, Preliminary Second Quarter Revenue and Reaffirms Full-Year 2022 Financial Guidance

Organizational updates are part of plan to bring additional focus on leveraging clinical data to accelerate market development and the pace of innovation

7 months ago - GlobeNewsWire

Axogen, Inc. Appoints William Burke to Board of Directors

Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of Directors Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of Di...

7 months ago - GlobeNewsWire

Axogen Aces Phase 3 Study For Avance Nerve Graft

Axogen Inc (NASDAQ: AXGN) announced topline results from its RECON Clinical Study comparing Avance Nerve Graft to conduits in digital nerve injuries.  Avance Nerve Graft is a biologically active off-t...

9 months ago - Benzinga

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Axogen, Inc Reports 2022 First Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...

9 months ago - GlobeNewsWire

Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft

RECON achieved its Primary Endpoint, a critical milestone toward transitioning Avance Nerve Graft to a licensed biologic and further supporting the expanded adoption of Avance RECON achieved its Prima...

9 months ago - GlobeNewsWire

Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022

ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...

10 months ago - GlobeNewsWire

Axogen, Inc. publishes inaugural ESG Report

ALACHUA, Fla. and TAMPA, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...

11 months ago - GlobeNewsWire

AxoGen (AXGN) Reports Q4 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 38.46% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research